Creating a new type of anticoagulant from carbohydrates
Official title: Development of anticoagulant sulfated glycans
Funded at Glycan Therapeutics Corporation · NIH-10907995 · Data updated 2026-11-12
This study is testing a new, safer blood thinner made from synthetic sugars that could replace animal-based options, aiming to help patients avoid risks linked to animal products.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycan Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Raleigh, UNITED STATES) |
| Project start | August 16, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,090,303 |
| NIH project number | 4R44GM148100-02 |
| Project ID | NIH-10907995 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients requiring anticoagulation therapy, particularly those who may be at risk for complications from traditional heparin treatments.
✕Less likely to help
Patients who do not require anticoagulation therapy or those with contraindications to anticoagulants may not benefit from this research.
What this research studies
This research focuses on developing a synthetic carbohydrate-based anticoagulant called sulfated glycan 8-mer to replace animal-derived low-molecular weight heparin (LMWH). The project aims to produce this compound using a novel chemoenzymatic method, which allows for a more consistent and safer alternative to current anticoagulants. The research will involve scaling up the production of the 8-mer and conducting pharmacodynamic analyses in advanced animal models to evaluate its effectiveness compared to existing treatments. Patients can benefit from a safer anticoagulant that reduces the risk of contamination and adverse reactions associated with animal-sourced products.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer and more effective anticoagulant option that minimizes the risk of contamination and adverse effects.
How similar studies have gone: While the approach of developing synthetic anticoagulants is being explored, this specific method using sulfated glycan 8-mer is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Glycan Therapeutics Corporation
Raleigh, United States Active
Researchers
- Principal investigator: Pagadala, Vijayakanth — Glycan Therapeutics Corporation
- Study coordinator: Pagadala, Vijayakanth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.